8-K: Owens & Minor Reports 4% Revenue Growth in Q2 2024, Driven by Both Segments

Owens & Minor announced a 4% year-over-year revenue increase in the second quarter of 2024, with growth in both its Products & Healthcare Services and Patient Direct segments, alongside a significant increase in operating cash flow.

Summary

• Owens & Minor reported a consolidated revenue of $2.7 billion for the second quarter of 2024, a 4% increase compared to the same period last year.
• The company experienced a net loss of $(32) million, or $(0.42) per share, in the second quarter.
• Adjusted EBITDA for the quarter was $127 million, a 12% increase year-over-year.
• Adjusted earnings per share doubled year-over-year from $0.18 to $0.36.
• Operating cash flow for the second quarter was $116 million, which enabled a $71 million reduction in debt.
• The Patient Direct segment saw a 4% revenue increase to $660 million, driven by strong growth in diabetes and sleep supplies.
• The Products & Healthcare Services segment also grew by 4%, reaching $2.0 billion in revenue, due to strong same-store sales and new wins in the Medical Distribution division.
• A one-time income tax charge of $17 million, or $0.22 per share, was recorded due to a recent decision related to past transfer pricing methodology.
• The company reaffirmed its 2024 financial guidance, projecting revenue between $10.5 billion and $10.9 billion, adjusted EBITDA between $550 million and $590 million, and adjusted EPS between $1.40 and $1.70.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth, EBITDA increase, and reaffirmed guidance, but tempered by the net loss and one-time tax charge. The company is performing as expected and is on track with its long term strategy.

Positives

• The company achieved a 4% increase in consolidated revenue, demonstrating growth in both major segments.
• Adjusted EBITDA saw a significant 12% year-over-year increase, indicating improved profitability.
• The company doubled its adjusted earnings per share year-over-year, showcasing strong financial performance.
• Operating cash flow was robust at $116 million, allowing for a substantial $71 million debt reduction.
• Both the Patient Direct and Products & Healthcare Services segments experienced 4% revenue growth.
• The company reaffirmed its full-year financial guidance, indicating confidence in future performance.

Negatives

• The company reported a net loss of $(32) million, or $(0.42) per share, for the second quarter.
• A one-time income tax charge of $17 million, or $0.22 per share, negatively impacted the quarter's results.
• The company expects a related cash payment of $30-$35 million in the second half of the year related to the tax matter.

Risks

• The company's 2024 outlook is subject to risks related to general economic conditions, including inflation.
• There is continued pressure on pricing and demand in the Products & Healthcare Services segment.
• The company's forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially.
• The company's non-GAAP financial measures may not be comparable to those used by other companies.

Future Outlook

The company reaffirmed its 2024 financial guidance, projecting revenue between $10.5 billion and $10.9 billion, adjusted EBITDA between $550 million and $590 million, and adjusted EPS between $1.40 and $1.70. The outlook is based on certain assumptions that are subject to the risk factors discussed in the company's filings with the SEC.

Management Comments

• Our second-quarter performance is consistent with our expectations, as we are in the early stages of implementing our long-term strategy discussed at Investor Day in December 2023.
• Our previous investments in our Products & Healthcare Services segment yielded positive results and generated top-line growth in our Medical Distribution division.
• Our Patient Direct segment performed in line with our expectations, and we expect the segment to benefit from seasonality and recent organic investments during the back half of the year, said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor.

Industry Context

The results reflect the ongoing trends in the healthcare industry, with a focus on both product distribution and direct patient care. The company's growth in both segments indicates a balanced approach to the market. The acquisition of Rotech Healthcare Holdings, while not included in the current outlook, suggests a strategic move to further expand the Patient Direct segment.

Comparison to Industry Standards

• Owens & Minor's 4% revenue growth is comparable to other large medical supply distributors, though specific competitor results would be needed for a more precise comparison.
• The 12% growth in adjusted EBITDA is a positive sign, suggesting improved operational efficiency compared to some peers who may be facing margin pressures.
• The company's focus on debt reduction aligns with industry trends of financial prudence, especially in the face of economic uncertainty.
• The reaffirmed financial guidance indicates a level of stability and predictability that is often sought by investors in the healthcare sector.
• Companies like Cardinal Health and McKesson, which are also major players in medical distribution, would be key comparables for a more detailed analysis of Owens & Minor's performance.

Stakeholder Impact

• Shareholders may view the revenue growth and EBITDA increase positively, but the net loss and tax charge may cause concern.
• Employees may be impacted by the ongoing Operating Model Realignment Program.
• Customers should see continued service and product availability.
• Suppliers may experience stable demand for their products.
• Creditors should be reassured by the company's debt reduction efforts.

Next Steps

• The company will host a conference call for investors and analysts on August 2, 2024, at 8:30 a.m. EDT.
• The company will continue to implement its long-term strategy and focus on growth in both segments.
• The company expects the Patient Direct segment to benefit from seasonality and recent organic investments in the second half of the year.
• The company will make a cash payment of $30-$35 million in the second half of the year related to the tax matter.

Key Dates

Keywords

revenue, EBITDA, earnings per share, healthcare, medical distribution, patient direct, financial results, debt reduction, operating cash flow, financial guidance